What should I know about BridgeBio Pharma?
BridgeBio Pharma is a US biotechnology company that develops medicines for genetic diseases, many of them rare. It was founded in 2015 and describes itself as a commercial-stage, multi-product biopharmaceutical company. Its first approved medicine, Attruby, treats ATTR-CM, and in the second quarter of 2026 three more programmes moved into active regulatory review. BridgeBio reported total revenue of $243.7 million for the quarter, a large part of which came from Attruby sales in the United States.
What are BridgeBio Pharma's main drugs?
BridgeBio's approved product is Attruby (acoramidis), a twice-daily pill that treats ATTR-CM. The FDA approved it in November 2024, and it is also approved in the EU (where it is called Beyonttra), Japan, Switzerland, Brazil and the UK. BridgeBio sells Atruby in the US, while Bayer holds European rights and Alexion (AstraZeneca) holds Japanese rights. Attruby generated $362.4 million in US net revenue in 2025 and $222.4 million in the second quarter of 2026 alone. Jefferies analysts expect Attruby to surpass $1 billion in annual global sales in 2026.
Attruby offers “near complete stabilization”, demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, and is cheaper than Pfizer’s Vyndamax, its main competitor. Following the failure of AstraZeneca and Ionis’s Wainua trial the decline in confidence in silencers as a treatment for ATTR-CM, BridgeBio’s Attruby, the leading stabilizer, looks set to expand market share rapidly.
What is BridgeBio Pharma currently developing?
BridgeBio has three potentially first-in-class late-stage programs under FDA review. BBP-418, for limb-girdle muscular dystrophy type 2I/R9, a rare progressive muscle disease with no approved treatment, has an FDA decision date of 27 November 2026. If approved, it would be the first treatment for this form of the disease and the first approved therapy for any form of limb-girdle muscular dystrophy. Phase 3 data showed improvements across key measures of walking and lung function while patients receiving placebo declined.
Encaleret targets autosomal dominant hypocalcaemia type 1, a rare calcium disorder for which there is no specifically indicated treatment. It is designed to address the underlying genetic cause and, in Phase 3, restored key measures of calcium regulation without calcium and vitamin D supplements. The FDA has set a decision date of 8 May 2027.
Oral infigratinib targets achondroplasia, the most common form of dwarfism. If approved, it would be the first and only oral treatment for children with the condition. Its Phase 3 study reported the largest improvement in annual height velocity seen in an achondroplasia Phase 3 trial, alongside the first statistically significant improvements in body proportionality and arm span. The FDA has granted priority review, with a decision expected on 4 February 2027.
Together, the three programmes could give BridgeBio a series of differentiated launches in diseases with substantial unmet need.
Is BridgeBio Pharma publicly traded, and how big is it?
Yes. BridgeBio trades on the Nasdaq under the ticker BBIO and went public in June 2019. Its market value was about $13 billion on 18 September 2026. Revenue is growing quickly, from $110.6 million in the second quarter of 2025 to $243.7 million in the same quarter of 2026. In July 2026, to support commercial stage development, Sixth Street and HealthCare Royalty – which is majority owned by Wall Street Giant KKR – agreed to invest up to $1 billion in BridgeBio in newly issued convertible preferred equity.